AR126544A1 - MULTIPARTICULATE PHARMACEUTICAL COMPOSITION - Google Patents
MULTIPARTICULATE PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR126544A1 AR126544A1 ARP220101943A ARP220101943A AR126544A1 AR 126544 A1 AR126544 A1 AR 126544A1 AR P220101943 A ARP220101943 A AR P220101943A AR P220101943 A ARP220101943 A AR P220101943A AR 126544 A1 AR126544 A1 AR 126544A1
- Authority
- AR
- Argentina
- Prior art keywords
- steps
- iii
- optionally
- pharmaceutical composition
- present
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 abstract 7
- 239000001856 Ethyl cellulose Substances 0.000 abstract 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 4
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 4
- 229920001249 ethyl cellulose Polymers 0.000 abstract 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 4
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 abstract 4
- 229960004002 levetiracetam Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008185 minitablet Substances 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000008298 dragée Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- -1 glidants Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona una composición farmacéutica sólida oral en forma de una composición multiparticulada que comprende un núcleo de liberación inmediata que comprende levetiracetam o una sal farmacéuticamente aceptable del mismo recubierto con una capa de liberación modificada, un procedimiento para la preparación de la composición de la invención, y su uso en terapia. Reivindicación 1: Una composición farmacéutica multiparticulada que comprende: a) una pluralidad de núcleos de liberación inmediata individuales que comprenden levetiracetam o una sal farmacéuticamente aceptable del mismo y uno o más excipientes seleccionados de diluyentes, aglutinantes, deslizantes, y lubricantes; en la que b) al menos aproximadamente el 50% de los núcleos de liberación inmediata individuales a) se encuentran recubiertos con una mezcla que comprende etilcelulosa e hidroxipropilmetilcelulosa que tiene una viscosidad comprendida entre aproximadamente 1 mPa×s y aproximadamente 1.000 mPa×s en una solución acuosa al 2% p/p a 20ºC, en donde la relación en peso de etilcelulosa a hidroxipropilmetilcelulosa está comprendida entre aproximadamente 4:1 y aproximadamente 20:1 y en la que la composición farmacéutica multiparticulada está en forma de mini-comprimidos, grageas y/o gránulos, preferiblemente mini-comprimidos. Reivindicación 12: Procedimiento para la preparación de una composición farmacéutica multiparticulada según una cualquiera de las reivindicaciones anteriores que comprende: i) proporcionar levetiracetam o una sal farmacéuticamente aceptable del mismo ii) opcionalmente mezclar dicho levetiracetam o una sal farmacéuticamente aceptable del mismo con un diluyente desde aproximadamente 1 min hasta aproximadamente 10 min, más preferiblemente desde aproximadamente 2 min hasta aproximadamente 7 min, incluso más preferiblemente durante aproximadamente 5 min; iii) opcionalmente granular la mezcla resultante de la etapa ii) con una disolución que comprende un aglutinante; iv) opcionalmente, secar el producto resultante de la etapa (i) o de las etapas (ii) y (iii) cuando estas etapas estén presentes, preferiblemente a una temperatura de desde aproximadamente 55ºC hasta 70ºC, preferiblemente de desde aproximadamente 60ºC hasta aproximadamente 65ºC, de manera más preferible de aproximadamente 60ºC; v) opcionalmente, mezclar el producto resultante de la etapa (i) o de las etapas (ii), (iii) y (iv) cuando estas etapas estén presentes con un deslizante, preferiblemente desde aproximadamente 5 min hasta aproximadamente 30 min, más preferiblemente desde 10 min hasta 20 min, incluso más preferiblemente durante aproximadamente 15 min; vi) opcionalmente, mezclar el producto resultante de la etapa (i) o de las etapas (ii), (iii), (iv) y (v) cuando estas etapas estén presentes, con un lubricante, preferiblemente desde aproximadamente 1 min hasta aproximadamente 10 min, más preferiblemente desde aproximadamente 2 min hasta aproximadamente 7 min, incluso más preferiblemente durante aproximadamente 5 min; vii) opcionalmente, comprimir el producto resultante de la etapa (i) o de las etapas (ii), (iii), (iv), (v) y (vi) cuando estas etapas estén presentes; viii)recubrir el producto resultante de la etapa (i) o de las etapas (ii), (iii), (iv), (v), (vi) y (vii) cuando estas etapas estén presentes con una mezcla que comprende etilcelulosa e hidroxipropilmetilcelulosa que tiene una viscosidad comprendida entre aproximadamente 1 mPa×s y aproximadamente 1.000 mPa×s en una solución acuosa al 2% p/p a 20ºC, en donde la relación en peso de etilcelulosa a hidroxipropilmetilcelulosa está comprendida entre aproximadamente 4:1 y aproximadamente 20:1; ix) curar la mezcla recubierta resultante de la etapa viii) preferiblemente a una temperatura de desde aproximadamente 15ºC hasta aproximadamente 30ºC, más preferiblemente de desde 20ºC hasta 25ºC. Reivindicación 14: Una composición farmacéutica multiparticulada según una cualquiera de las reivindicaciones 1 a 11, para su uso en el tratamiento de la epilepsia.The present invention provides an oral solid pharmaceutical composition in the form of a multiparticulate composition comprising an immediate release core comprising levetiracetam or a pharmaceutically acceptable salt thereof coated with a modified release layer, a process for the preparation of the composition of the invention, and its use in therapy. Claim 1: A multiparticulate pharmaceutical composition comprising: a) a plurality of individual immediate release cores comprising levetiracetam or a pharmaceutically acceptable salt thereof and one or more excipients selected from diluents, binders, glidants, and lubricants; wherein b) at least about 50% of the individual immediate release cores a) are coated with a mixture comprising ethylcellulose and hydroxypropylmethylcellulose having a viscosity between about 1 mPa×s and about 1,000 mPa×s in a solution 2% w/w aqueous at 20°C, wherein the weight ratio of ethylcellulose to hydroxypropylmethylcellulose is between approximately 4:1 and approximately 20:1 and wherein the multiparticulate pharmaceutical composition is in the form of mini-tablets, dragees and/or or granules, preferably mini-tablets. Claim 12: Procedure for the preparation of a multiparticulate pharmaceutical composition according to any one of the preceding claims comprising: i) providing levetiracetam or a pharmaceutically acceptable salt thereof ii) optionally mixing said levetiracetam or a pharmaceutically acceptable salt thereof with a diluent from about 1 min to about 10 min, more preferably from about 2 min to about 7 min, even more preferably for about 5 min; iii) optionally granulate the mixture resulting from step ii) with a solution comprising a binder; iv) optionally, drying the product resulting from step (i) or steps (ii) and (iii) when these steps are present, preferably at a temperature of from approximately 55ºC to 70ºC, preferably from approximately 60ºC to approximately 65ºC , more preferably about 60°C; v) optionally, mixing the product resulting from step (i) or steps (ii), (iii) and (iv) when these steps are present with a slider, preferably from about 5 min to about 30 min, more preferably from 10 min to 20 min, even more preferably for about 15 min; vi) optionally, mix the product resulting from step (i) or steps (ii), (iii), (iv) and (v) when these steps are present, with a lubricant, preferably from about 1 min to about 10 min, more preferably from about 2 min to about 7 min, even more preferably for about 5 min; vii) optionally, compress the product resulting from step (i) or steps (ii), (iii), (iv), (v) and (vi) when these steps are present; viii) coating the product resulting from step (i) or steps (ii), (iii), (iv), (v), (vi) and (vii) when these steps are present with a mixture comprising ethylcellulose and hydroxypropylmethylcellulose having a viscosity between about 1 mPa×s and about 1,000 mPa×s in a 2% w/w aqueous solution at 20°C, wherein the weight ratio of ethylcellulose to hydroxypropylmethylcellulose is between about 4:1 and about 20 :1; ix) curing the coated mixture resulting from step viii) preferably at a temperature of from about 15°C to about 30°C, more preferably from 20°C to 25°C. Claim 14: A multiparticulate pharmaceutical composition according to any one of claims 1 to 11, for use in the treatment of epilepsy.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21382672 | 2021-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126544A1 true AR126544A1 (en) | 2023-10-18 |
Family
ID=77168154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101943A AR126544A1 (en) | 2021-07-23 | 2022-07-22 | MULTIPARTICULATE PHARMACEUTICAL COMPOSITION |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4373473A1 (en) |
AR (1) | AR126544A1 (en) |
AU (1) | AU2022315552A1 (en) |
CA (1) | CA3226799A1 (en) |
WO (1) | WO2023002004A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006088864A1 (en) | 2005-02-16 | 2006-08-24 | Elan Pharma International Limited | Controlled release compositions comprising levetiracetam |
US20120003307A1 (en) | 2007-11-29 | 2012-01-05 | Ranbaxy Laboratories Limited | Levetiracetam controlled release composition |
US20100172979A1 (en) | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
WO2011049309A2 (en) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | Pharmaceutical composition with both immediate and extended release characteristics |
WO2011107855A2 (en) | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
WO2014025593A1 (en) | 2012-08-08 | 2014-02-13 | PharmTak, Inc. | Extended-release levetiracetam and method of preparation |
-
2022
- 2022-07-22 AU AU2022315552A patent/AU2022315552A1/en active Pending
- 2022-07-22 EP EP22755145.4A patent/EP4373473A1/en active Pending
- 2022-07-22 CA CA3226799A patent/CA3226799A1/en active Pending
- 2022-07-22 WO PCT/EP2022/070585 patent/WO2023002004A1/en active Application Filing
- 2022-07-22 AR ARP220101943A patent/AR126544A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4373473A1 (en) | 2024-05-29 |
WO2023002004A1 (en) | 2023-01-26 |
CA3226799A1 (en) | 2023-01-26 |
AU2022315552A1 (en) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800115A (en) | PYRIDINYLTRIAZOLE DERIVATIVES SUBSTITUTED WITH AMIDE AND USES OF THESE | |
HN2005000484A (en) | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | |
CR20230330A (en) | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | |
BR9809484A (en) | Enteric coated oral pharmaceutical formulation, process for manufacturing it, using a low viscosity hydroxypropyl methylcellulose (hpmc) quality, and process for the treatment of gastrointestinal diseases in mammals, including man. | |
PA8493701A1 (en) | COMPOUNDS TO TREAT OBESITY | |
UY27446A1 (en) | NEW COMPOUNDS | |
CL2013003816A1 (en) | Compounds derived from carboxamide and urea comprising aromatic substituted pyrazole, vanilloid receptor binders; pharmaceutical composition that includes them; and its use in the treatment and / or prophylaxis of pain, migraine, parkinson's disease, gastrointestinal disorders, osteoporosis, among other diseases. | |
UY29087A1 (en) | ADAMANTILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USE | |
AR010752A1 (en) | COMPOUNDS WHICH BIND TO AND ACTIVATE A THROMBOPOYETINE RECEPTOR; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, THEIR USE FOR THE PREPARATION OF MEDICINES, AND PROCESS TO PREPARE SUCH COMPOSITION. | |
AR053162A1 (en) | COMPOUND 5 - OXO - REPLACED PIRROLIDIN, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA. | |
CO5390079A1 (en) | NEW HETEROCICLIC COMPOUNDS THAT HAVE HYPOLIPIDEMIC, HYPOCOLESTEROLIC ACTIVITIES, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE IN MEDICINE | |
UY29875A1 (en) | CHEMICAL COMPOUNDS | |
EP1928236A4 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
GT200600163A (en) | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
BRPI0509194A (en) | formulation and method of coated tablet | |
ECSP22018571A (en) | BIFUNCTIONAL DEGRADATORS OF BRD9 AND THEIR METHODS OF USE | |
AR033377A1 (en) | DERIVATIVES OF BENZOCICLOALQUILENILAMINA AS ANTAGONISTS OF MUSCARINIC RECEPTORS | |
UY29181A1 (en) | DERIVATIVES OF N-REPLACED BENCENOSULPHONAMIDS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCESSES AND APPLICATIONS | |
CL2004000590A1 (en) | COMPOUNDS DERIVED FROM 1,3,4-OXADIAZOL-3-ONA, 1,3,4-TIADIAZOL-2-ONA AND 1,2,4-TRIAZOL-3-ONA; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; PREPARATION PROCEDURE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT IN WHICH VIRUS V IS RELATED | |
ECSP20062464A (en) | PIPERIDINYL-3- (ARYLOXY) PROPANAMIDES AND PROPANOATES | |
ECSP088366A (en) | 1,2-DIARILIMIDAZOLES FOR USE AS CB1 MODULATORS | |
BRPI0508560A (en) | use of cb1 receptor antagonists to produce a composition useful for the treatment of liver disease | |
BRPI0517369A (en) | compounds, process for their manufacture, compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with modulation of cb1 receptors and their use | |
MX2023008330A (en) | Compositions and methods for the treatment of metabolic and liver disorders. | |
AR126544A1 (en) | MULTIPARTICULATE PHARMACEUTICAL COMPOSITION |